Genmab — December 2019
-
Relapsed/refractory patients
Ixazomib, thalidomide, and dexamethasone for relapsed/refractory multiple myeloma https://multiplemyelomahub.com/medical-information/ixazomib-thalidomide-and-dexamethasone-for-relapsed-refractory-multiple-myeloma -
Jo Ixazomib er bekvemmelig, da den er oral, men prøv at tjekke hvad Kræftens Bekæmpelse skriver om den: https://www.cancer.dk/myelomatose-knoglemarvskraeft/behandling-myelomatose/behandling-rettet-mod-myelomatosecellerne/myelomatose-proteasomhaemmere/
-
SEB løfter kursen til 1535 fra 1200 https://penge.borsen.dk/artikel/1/392345/seb_loefter_genmab-kursmaal_til_1535_kr_fra_1200_kr.html
-
-
Vincent Rajkumar
@VincentRK
Of the top 100,000 most cited researchers in the world across all scientific fields, ~75 are myeloma researchers. Proud that 13 are from @MayoClinic
@MayoMyeloma
@MayoCancerCare -
God morgen.
-
-
Generelt er det en god ide at lytte til Genmabchatten, hvis du vil vide noget om Genmab som f.eks at den er underpriset gennem et par år, grundet dårlige analytikere og PE-folket der ikke fatter hvad type virksomhed der er tale om. At stigningen skyldes nævnte + ASH, shortere ud, milestone som lige er tikket ind, positionering til guiding og mulig nyt fra pipeline, samarbejdspartnere og andet spændende.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind